Advertisement

Medication-Overuse Headache (MOH)

  • Zaza KatsaravaEmail author
Part of the Headache book series (HEAD)

Abstract

Overuse of any kind of acute headache/migraine drugs can lead to the development of medication-overuse headache. People suffering from primary headache such as migraine or tension-type headache are at higher risk to develop chronic headache following the overuse of acute headache drugs. Treatment of medication-overuse headache requires multidisciplinary setting and includes education of patients, withdrawal as an initial step, and initiation of preventive treatment.

Keywords

Cluster Headache Migraine Attack Chronic Migraine Chronic Daily Headache Chronic Headache 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ashina S, Lyngberg A, Jensen R (2010) Headache characteristics and chronification of migraine and tension-type headache: a population-based study. Cephalalgia 30:943–952PubMedGoogle Scholar
  2. 2.
    Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Reed ML, Buse DC (2012) Depression and risk of transformation of episodic to chronic migraine. J Headache Pain 13:615–624PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M (2005) Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain 9:285–291PubMedCrossRefGoogle Scholar
  4. 4.
    Ayzenberg I, Obermann M, Nyhuis P et al (2006) Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 26:1106–1114PubMedCrossRefGoogle Scholar
  5. 5.
    Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ (2012) Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia 32:373–381PubMedCrossRefGoogle Scholar
  6. 6.
    Bahra A, Walsh M, Menon S, Goadsby PJ (2003) Does chronic daily headache arise de novo in association with regular analgesic use? Headache 43:179–190PubMedCrossRefGoogle Scholar
  7. 7.
    Baumgartner C, Wessely P, Bingol C, Maly J, Holzner F (1989) Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 29:510–514PubMedCrossRefGoogle Scholar
  8. 8.
    Bendtsen L, Jensen R, Olesen J (1996) Decreased pain detection and tolerance thresholds in chronic tension-type headache. Arch Neurol 53:373–376PubMedCrossRefGoogle Scholar
  9. 9.
    Bigal ME, Liberman JN, Lipton RB (2006) Obesity and migraine. A population study. Neurology 66:545–550PubMedCrossRefGoogle Scholar
  10. 10.
    Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population based study. Headache 48:1157–1168PubMedCrossRefGoogle Scholar
  11. 11.
    Boe MG, Mygland A, Salvesen R (2007) Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology 69:26–31PubMedCrossRefGoogle Scholar
  12. 12.
    Boe MG, Salvesen R, Mygland A (2009) Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol 16:705–712PubMedCrossRefGoogle Scholar
  13. 13.
    Castillo J, Munoz P, Guitera V, Pascual J (1999) Epidemiology of chronic daily headache in the general population. Headache 39:190–196PubMedCrossRefGoogle Scholar
  14. 14.
    Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zangini S, Nicodemo M, Cortelli P, Montagna P (2009) Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache 49:412–418PubMedCrossRefGoogle Scholar
  15. 15.
    Colas R, Munoz P, Temprano R, Gomez C, Pascual J (2004) Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 27:1338–1342CrossRefGoogle Scholar
  16. 16.
    Coskun O, Ucler S, Cavdar L, Inan LE (2007) Effect of valproic acid on withdrawal therapy in patients with overuse of chronic daily headache medications. J Clin Neurosci 14:334–339PubMedCrossRefGoogle Scholar
  17. 17.
    Creac’h C, Radat F, Mick G, Guegan-Massardier E, Giraud P, Guy N, Fabre N, Nachit-Quinekh F, Lanteri-Minet M (2009) One or several types of triptan overuse headaches? Headache 49:519–528PubMedCrossRefGoogle Scholar
  18. 18.
    Créac’h C, Frappe P, Cancade M, Laurent B, Peyron R, Demarquay G, Navez M (2011) In-patient versus out-patient withdrawal programmes for medication overuse headache: a 2-year randomized trial. Cephalalgia 31:1189–1198PubMedCrossRefGoogle Scholar
  19. 19.
    Currà A, Coppola G, Gorini M, Porretta E, Bracaglia M, Di Lorenzo C, Schoenen J, Pierelli F (2011) Drug induced changes in cortical inhibition in medication overuse headache. Cephalalgia 31:1282–1290PubMedCrossRefGoogle Scholar
  20. 20.
    da Silva JA, Costa EC, Gomes JB, Leite FM, Gomez RS, Vasconcelos LP, Krymchantowski A, Moreira P, Teixeira AL (2010) Chronic headache and comorbibities: a two-phase, population-based, cross-sectional study. Headache 50:1306–1312PubMedCrossRefGoogle Scholar
  21. 21.
    De Felice M, Ossipov MH, Wang R, Dussor G, Lai J, Meng ID, Chichorro J, Andrews JS, Rakhit S, Maddaford S, Dodick D, Porreca F (2010) Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 133:2475–2488PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    de Tommaso M, Libro G, Guido M, Sciruicchio V, Losito L, Puca F (2003) Heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in chronic tension-type headache. Pain 104:111–119PubMedCrossRefGoogle Scholar
  23. 23.
    deSouza RM, Toma A, Watkins L (2014) Medication overuse headache – an under-diagnosed problem in shunted idiopathic intracranial hypertension patients. Br J Neurosurg 19:1–5Google Scholar
  24. 24.
    Di Lorenzo C, Sances G, Di Lorenzo G, Rengo C, Ghiotto N, Guaschino E, Perrotta A, Santorelli FM, Grieco GS, Troisi A, Siracusano A, Pierelli F, Nappi G, Casali C (2007) The Wolframin His 611Arg polymorphism influences medication overuse headache. Neurosci Lett 424:179–184PubMedCrossRefGoogle Scholar
  25. 25.
    Diaz-Mitoma F, Vanast WJ, Tyrrell DL (1987) Increased frequency of Epstein-Barr-virus excretion in patients with new daily persistent headaches. Lancet 1:411–414PubMedCrossRefGoogle Scholar
  26. 26.
    Diener HC, Dahlof CG (1999) Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KM (eds) The headaches, 2nd edn. Lippincott, Williams & Wilkins, Philadelphia, pp 871–878Google Scholar
  27. 27.
    Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A (1989) Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 236:9–14PubMedCrossRefGoogle Scholar
  28. 28.
    Diener HC, Wilkinson M (1988) Drug-induced headache. Springer, New-YorkCrossRefGoogle Scholar
  29. 29.
    Diener HC, Evers S, Fritsche G, Katsarava Z, Kropp P, Limmroth V, May A, Meyer U, Pfaffenrath V. Medication overuse headache. In: Diener HC (ed) Guidelines of the German Society of neurology. Thieme Verlag 2009.Google Scholar
  30. 30.
    Dobson CF, Tohyama Y, Diksic M, Hamel E (2004) Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 24:2–11PubMedCrossRefGoogle Scholar
  31. 31.
    Evers S, Suhr B, Bauer B, Grotemeyer KH, Husstedt IW (1999) A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol 246:802–809PubMedCrossRefGoogle Scholar
  32. 32.
    Ferraro S, Grazzi L, Mandelli ML, Aquino D, Di Fiore D, Usai S, Bruzzone MG, Di Salle F, Bussone G, Chiapparini L (2012) Pain processing in medication overuse headache: a functional magnetic resonance imaging (fMRI) Study. Pain Med 13:255–262PubMedCrossRefGoogle Scholar
  33. 33.
    Fisher MA, Glass S (1997) Butorphanol (Stadol): a study in problems of current drug information and control. Neurology 48:1156–1160PubMedCrossRefGoogle Scholar
  34. 34.
    Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC (2001) Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 45:229–235PubMedCrossRefGoogle Scholar
  35. 35.
    Fritsche G, Frettloöh J, Hüppe M, Dlugaj M, Matatko N, Gaul C, Diener HC (2010) Prevention of medication overuse in patients with migraine. Pain 151:404–413PubMedCrossRefGoogle Scholar
  36. 36.
    Fumal A, Laureys S, Di Clemente L et al (2006) Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 129:543–550PubMedCrossRefGoogle Scholar
  37. 37.
    Gaul C, van Doorn C, Webering N, Dlugaj M, Katsarava Z, Diener HC, Fritsche G (2011) Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain 12:475–483PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Goadsby PJ (1997) How do the currently used prophylactic agents work in migraine? Cephalalgia 17:85–92PubMedCrossRefGoogle Scholar
  39. 39.
    Grande RB, Aaseth K, Saltyte-Benth J, Gulbrandsen P, Russel MB, Lundquist C (2009) The severity of Dependence Scale detects people with medication overuse: Akershus study of chronic headache. J Neurol Neurosurg Psychiatry 80:784–789PubMedCrossRefGoogle Scholar
  40. 40.
    Grazzi L, Andrasik F, D’Amico D et al (2002) Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 42:483–490PubMedCrossRefGoogle Scholar
  41. 41.
    Griffiths RR, Woodson PP (1988) Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology (Berl) 94:437–451CrossRefGoogle Scholar
  42. 42.
    Griffiths RR, Woodson PP (1988) Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav 29:419–427PubMedCrossRefGoogle Scholar
  43. 43.
    Gutzwiller F, Zemp E (1986) Der Analgetikakonsum in der Bevölkerung und socioökonomische Aspekte des Analgetikaabusus. In: Mihatsch MJ (ed) Das Analgetikasyndrom. Thieme, Stutgart, p 197Google Scholar
  44. 44.
    Hagen K, Vatten L, Stovner LJ et al (2002) Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia 22:672–679PubMedCrossRefGoogle Scholar
  45. 45.
    Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA (2012) Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain 153:56–61PubMedCrossRefGoogle Scholar
  46. 46.
    Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl 7):1–93Google Scholar
  47. 47.
    Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders 3rd edition (beta version). Cephalalgia 33(9):629–808CrossRefGoogle Scholar
  48. 48.
    Horton BT, Peters GA (1963) Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 3:214–226CrossRefGoogle Scholar
  49. 49.
    Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G (2003) Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 60:1682–1683PubMedCrossRefGoogle Scholar
  50. 50.
    Katsarava Z, Schneeweiss S, Kurth T et al (2004) Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62:788–790PubMedCrossRefGoogle Scholar
  51. 51.
    Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti M, Janelidze M, Jensen R, Stovner LJ, Steiner TJ (2009) Primary headache disorders in the Republic of Georgia: prevalence and risk factors. Neurology 73:1796–1803PubMedCrossRefGoogle Scholar
  52. 52.
    Kaube H, May A, Diener HC, Pfaffenrath V (1994) Sumatriptan misuse in daily chronic headache. BMJ 308:1573PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Kavuk I, Weimar C, Kim BT et al (2006) One-year prevalence and socio-cultural aspects of chronic headache in Turkish immigrants and German natives. Cephalalgia 26:1177–1181PubMedCrossRefGoogle Scholar
  54. 54.
    Krymchantowski AV, Barbosa JS (2000) Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 20:107–113PubMedCrossRefGoogle Scholar
  55. 55.
    Lance F, Parkes C, Wilkinson M (1988) Does analgesic abuse cause headache de novo? Headache 38:61–62CrossRefGoogle Scholar
  56. 56.
    Lanteri-Minet M, Auray JP, El Hasnaoui A et al (2003) Prevalence and description of chronic daily headache in the general population in France. Pain 102:143–149PubMedCrossRefGoogle Scholar
  57. 57.
    Limmroth V, Kazarawa S, Fritsche G, Diener HC (1999) Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 353:378PubMedCrossRefGoogle Scholar
  58. 58.
    Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC (2002) Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59:1011–1014PubMedCrossRefGoogle Scholar
  59. 59.
    Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ (2001) Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 21:980–986PubMedCrossRefGoogle Scholar
  60. 60.
    Meskunas CA, Tepper SJ, Rapoport AM et al (2006) Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 46:766–772PubMedCrossRefGoogle Scholar
  61. 61.
    Moore AJ, Shevell M (2004) Chronic daily headaches in pediatric neurology practice. J Child Neurol 19:925–929PubMedGoogle Scholar
  62. 62.
    Newman LC, Lipton RB, Russell M, Solomon S (1992) Hemicrania continua: attacks may alternate sides. Headache 32:237–238PubMedCrossRefGoogle Scholar
  63. 63.
    Newman LC, Lipton RB, Solomon S (1993) Hemicrania continua: 7 new cases and a literature review. Headache 32:267Google Scholar
  64. 64.
    Olesen J, Bousser MG, Diener HC et al (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746PubMedCrossRefGoogle Scholar
  65. 65.
    Olesen J, Lipton RB (2004) Headache classification update 2004. Curr Opin Neurol 17:275–282PubMedCrossRefGoogle Scholar
  66. 66.
    Pageler L, Katsarava Z, Diener HC, Limmroth V (2008) Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia 28:152–156PubMedGoogle Scholar
  67. 67.
    Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ (2006) Medication-overuse headache in patients with cluster headache. Neurology 67:109–113PubMedCrossRefGoogle Scholar
  68. 68.
    Park JW, Kim JS, Kim YI, Lee KS (2005) Serotonergic activity contributes to analgesic overuse in chronic tension-type headache. Headache 45:1229–1235PubMedCrossRefGoogle Scholar
  69. 69.
    Park JW, Moon HS, Kim JM, Lee KS, Chu MK (2014) Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management. J Clin Neurol 10:236–243PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Peters GA, Horton BT (1951) Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc Staff Meet Mayo Clin 26:153–161PubMedGoogle Scholar
  71. 71.
    Piazza F, Chiappedi M, Maffioletti E, Galli F, Balottin U (2012) Medication overuse headache in school-aged children: more common than expected? Headache 52:1506–1510PubMedCrossRefGoogle Scholar
  72. 72.
    Pini LA, Cicero AF, Sandrini M (2001) Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 21:878–883PubMedCrossRefGoogle Scholar
  73. 73.
    Prencipe M, Casini AR, Ferretti C et al (2001) Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 70:377–381PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Radat F, Creac’h C, Swendsen JD et al (2005) Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 25:519–522PubMedCrossRefGoogle Scholar
  75. 75.
    Raskin NH (1986) Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 36:995–997PubMedCrossRefGoogle Scholar
  76. 76.
    Reuter U, Salomone S, Ickstein GW, Waeber C (2004) Effects of chronic sumatriptan and zolmitriptan treatment on 5-HAT receptor expression and function in rats. Cephalalgia 24:398–407PubMedCrossRefGoogle Scholar
  77. 77.
    Riederer F, Marti M, Luechinger R, Lanzenberger R, von Meyenburg J, Gantenbein AR, Pirrotta R, Gaul C, Kollias S, Sándor PS (2012) Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry 13:517–525PubMedCrossRefGoogle Scholar
  78. 78.
    Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G (2006) Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 26:1097–1105PubMedCrossRefGoogle Scholar
  79. 79.
    Rossi P, Faroni JV, Tassorelli C, Nappi G (2013) Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain 14:10PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Sancisi E, Cevoli S, Vignatelli L, Nicodemo M, Pierangeli G, Zanigni S, Grimaldi D, Cortelli P, Montagna P (2010) Increased prevalence of sleep disorders in chronic headache: a case-control study. Headache 50:1464–1472PubMedCrossRefGoogle Scholar
  81. 81.
    Scher AI, Stewart WF, Lipton RB (2004) Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 63:2022–2027PubMedCrossRefGoogle Scholar
  82. 82.
    Scher AI, Stewart WF, Ricci JA, Lipton RB (2003) Factors associated with the onset and remission of chronic daily headache in a population–based study. Pain 106:81–89PubMedCrossRefGoogle Scholar
  83. 83.
    Schmidt-Wilcke T, Leinisch E, Straube A et al (2005) Gray matter decrease in patients with chronic tension type headache. Neurology 65:1483–1486PubMedCrossRefGoogle Scholar
  84. 84.
    Schnider P, Aull S, Baumgartner C et al (1996) Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five year follow-up. Cephalalgia 16:481–485PubMedCrossRefGoogle Scholar
  85. 85.
    Schwarz A, Farber U, Glaeske G (1985) Daten zu Analgetikakonsum und Analgetikanephropathie in der Bundesrepublik. Öffent Gesundheitswes 47:298Google Scholar
  86. 86.
    Shah AM, Bendtsen L, Zeeberg P, Jensen RH (2013) Reduction of medication costs after detoxification for medication-overuse headache. Headache 53:665–672PubMedCrossRefGoogle Scholar
  87. 87.
    Silberstein SD, Schulman EA, McFaden Hopkins M (1990) Repetitive intravenous DHE in the treatment of refractory headache. Headache 30:334–339PubMedCrossRefGoogle Scholar
  88. 88.
    Silberstein SD, Silberstein JR (1992) Chronic daily headache: long-term prognosis following inpatient treatment with repetitive intravenous DHE. Headache 32:439–445PubMedCrossRefGoogle Scholar
  89. 89.
    Silverman K, Evans SM, Strain EC, Griffiths RR (1992) Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 327:1109–1114PubMedCrossRefGoogle Scholar
  90. 90.
    Srikiatkhachorn A, Anthony M (1996) Platelet serotonin in patients with analgesic-induced headache. Cephalalgia 16:423–426PubMedCrossRefGoogle Scholar
  91. 91.
    Srikiatkhachorn A, Tarasub N, Govitrapong P (2000) Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 40:343–350PubMedCrossRefGoogle Scholar
  92. 92.
    Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, Vennemann M, Berger K (2010) Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study. Cephalalgia 30:207–213PubMedCrossRefGoogle Scholar
  93. 93.
    Suhr B, Evers S, Bauer B, Gralow I, Grotemeyer KH, Husstedt IW (1999) Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia 19:44–49PubMedCrossRefGoogle Scholar
  94. 94.
    Terrazzino S, Sances G, Balsamo F, Viana M, Monaco F, Bellomo G, Martignoni E, Tassorelli C, Nappi G, Canonico PL, Genazzani AA (2010) Role of 2 common variants of 5HT2A gene in medication overuse headache. Headache 50:1587–1596PubMedCrossRefGoogle Scholar
  95. 95.
    Tfelt-Hansen P (1995) Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Cephalalgia S15:29–32Google Scholar
  96. 96.
    Tfelt-Hansen P, Krabbe AA (1981) Ergotamine abuse: do patients benefit from withdrawal? Cephalalgia 1:29–31PubMedCrossRefGoogle Scholar
  97. 97.
    Tohyama Y, Yamane F, Fikre Merid M, Blier P, Diksic M (2002) Effects of serotonin receptor agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain: an autoradiographic study. J Neurochem 80:788–798PubMedCrossRefGoogle Scholar
  98. 98.
    Tribl GG, Schnider P, Wober C et al (2001) Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia 21:691–696PubMedCrossRefGoogle Scholar
  99. 99.
    van Dusseldorp M, Katan MB (1990) Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. Br Med J 300:1558–1559CrossRefGoogle Scholar
  100. 100.
    Wang SJ, Fuh JL, Lu SR et al (2000) Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 54:314–319PubMedCrossRefGoogle Scholar
  101. 101.
    Wang SJ, Fuh JL, Lu SR, Juang KD (2006) Chronic daily headache in adolescents. Prevalence, impact, and medication overuse. Neurology 66:193–197PubMedCrossRefGoogle Scholar
  102. 102.
    Westergaard ML, Glümer C, Hansen EH, Jensen RH (2014) Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 11:S0304–S3959Google Scholar
  103. 103.
    Wiendels NJ, Knuistingh Neven A, Rosendaal FR et al (2006) Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia 26:1434–1442PubMedCrossRefGoogle Scholar
  104. 104.
    Williams DR, Stark RJ (2003) Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 23:963–971PubMedCrossRefGoogle Scholar
  105. 105.
    Willer L, Jensen RH, Juhler M (2010) Medication overuse as a cause of chronic headache in shunted hydrocephalus patients. J Neurol Neurosurg Psychiatry 81:1261–1264PubMedCrossRefGoogle Scholar
  106. 106.
    Zeeberg P, Olesen J, Jensen R (2006) Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 66:1894–1898PubMedCrossRefGoogle Scholar
  107. 107.
    Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, Sternic N (2007) Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 27:1219–1225PubMedCrossRefGoogle Scholar
  108. 108.
    Ziegler DK (1994) Opiate and opioid use in patients with refractory headache. Cephalalgia 14:5–10PubMedCrossRefGoogle Scholar
  109. 109.
    Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J (2003) Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 61:160–164PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of NeurologyEvangelical HospitalUnnaGermany

Personalised recommendations